Defining CRO vs Sponsor Roles in Clinical Trial Site Activation Planning

Introduction: The Importance of Role Clarity in Activation

Site activation in global clinical trials requires meticulous planning, coordination, and execution. Both sponsors and Contract Research Organizations (CROs) play pivotal roles in this process, but blurred responsibilities can lead to delays, duplicated efforts, or compliance risks. Regulatory bodies such as the FDA, EMA, and MHRA emphasize that while sponsors may delegate trial activities to CROs, ultimate responsibility for trial conduct remains with the sponsor. Understanding how responsibilities are shared, delegated, and monitored during activation planning ensures smoother trial startup and inspection readiness.

This article provides a comprehensive overview of CRO vs sponsor roles in activation planning, highlighting areas of overlap, delegation, and accountability.

1. Sponsor Responsibilities in Activation Planning

Sponsors retain ultimate accountability for site activation. Core responsibilities include:

• Protocol Ownership: Sponsors develop and finalize trial protocols
• Regulatory Submissions: IND/CTA submissions to health authorities
• Site Contracts: Oversight of budget negotiations and contract templates
• Oversight of CRO Activities: Ensuring delegated tasks are monitored
• Final Greenlight: Authorizing sites to proceed with recruitment

Sponsors are legally responsible for trial compliance under ICH-GCP E6(R2), regardless of CRO involvement.

2. CRO Responsibilities in Activation Planning

CROs execute the operational aspects of site activation on behalf of sponsors. Key responsibilities include:

• Conducting feasibility assessments and site selection
• Coordinating ethics submissions and approvals
• Managing essential document collection and validation
• Organizing Site Initiation Visits (SIVs)
• Tracking activation milestones in CTMS
• Ensuring regulatory binder/ISF setup

CROs act as the operational arm of the sponsor but must work within sponsor-approved SOPs and frameworks.

3. Overlapping Responsibilities

Certain activation responsibilities are shared between CROs and sponsors. Examples include:

• Contract Negotiations: CROs may handle administrative back-and-forth, but sponsors approve final terms
• Budget Approvals: CROs draft and negotiate; sponsors provide final sign-off
• Greenlight Decisions: CROs recommend readiness, sponsors confirm activation
• Training Oversight: CROs deliver protocol/GCP training, sponsors ensure completion is verified

These overlaps require structured communication to avoid duplication or missed steps.

4. RACI Model for Activation Planning

The RACI (Responsible, Accountable, Consulted, Informed) model provides clarity on task division. A sample framework:

5. Communication Challenges in CRO–Sponsor Activation

Common issues that cause startup delays include:

• Lack of clear delegation documented in contracts or scope of work (SOW)
• Delayed sponsor responses to CRO queries
• Redundant document requests due to poor coordination
• Misalignment in expectations for activation timelines

Clear communication pathways, escalation procedures, and joint governance meetings mitigate these risks.

6. Technology in Role Division

Modern digital tools improve role clarity and efficiency:

• CTMS: Shared milestone tracking for activation
• eTMF: Provides real-time visibility of document readiness
• Dashboards: Sponsor and CRO dashboards display bottlenecks and role ownership
• Collaboration Platforms: Streamline communication across time zones

Using shared technology platforms reduces misunderstandings and fosters accountability.

7. Case Study: CRO–Sponsor Alignment in Oncology Trial

Scenario: A global oncology trial involving 80 sites across 15 countries faced repeated delays in contract approvals. CROs managed negotiations, but sponsor legal teams were slow to approve final templates.

Resolution: The sponsor implemented a contract playbook with pre-approved clauses, allowing CROs to finalize 80% of contracts without further sponsor review. Activation timelines were reduced by 35 days on average.

8. Best Practices for Role Clarity

• Define sponsor vs CRO responsibilities in the scope of work
• Use RACI models to document accountability
• Adopt contract playbooks and standardized negotiation templates
• Hold joint startup governance calls weekly
• Ensure mutual access to CTMS/eTMF for transparency

Conclusion

Successful site activation requires seamless coordination between sponsors and CROs. While CROs execute much of the operational work, sponsors retain ultimate accountability under regulatory guidelines. By clearly defining roles, leveraging technology, and institutionalizing best practices, both parties can minimize activation delays and ensure inspection-ready documentation. Role clarity is not just an operational necessity—it is a compliance imperative that safeguards the integrity and success of global clinical trials.

Sponsor Approaches to Auditing CRO Data Management

Introduction: Why Sponsor Oversight of CRO Data Matters

Clinical trial sponsors hold ultimate regulatory responsibility for the quality and integrity of trial data, even when tasks are outsourced to Contract Research Organizations (CROs). This makes the audit of CRO data management practices a cornerstone of oversight. Whether dealing with Electronic Data Capture (EDC) platforms, eTMF systems, or vendor-provided datasets, sponsors must demonstrate effective control to regulators under ICH GCP E6(R2/R3) and 21 CFR Part 11.

Regulatory agencies such as the FDA, EMA, and MHRA routinely issue inspection observations when sponsors fail to adequately audit their CRO partners. Typical findings include unvalidated systems, incomplete audit trails, or insufficient vendor oversight. A structured, risk-based audit program enables sponsors to detect issues early, ensure compliance, and safeguard trial integrity.

Regulatory Expectations for Sponsor Oversight

Guidelines mandate that sponsors cannot delegate ultimate responsibility for data integrity. Specific expectations include:

• Documenting CRO oversight within Quality Agreements.
• Conducting vendor qualification audits before study initiation.
• Performing periodic process audits to ensure ongoing compliance.
• Verifying system validation status of CRO-managed platforms.
• Ensuring that data transfer agreements define responsibilities and controls.

In one recent FDA inspection, a sponsor was cited for relying solely on CRO self-assessments, without conducting independent audits. This underscores the regulator’s expectation of active and documented sponsor engagement.

Audit Scope for CRO Data Management

When sponsors plan audits of CROs, the scope must be comprehensive. Key focus areas include:

Case Example: Sponsor Audit of CRO eTMF

A sponsor conducted an audit of a CRO’s electronic Trial Master File (eTMF) and discovered missing metadata for 15% of uploaded documents. The CRO lacked a formal reconciliation process. The sponsor issued a major observation, requiring the CRO to implement automated completeness checks. Follow-up audits confirmed improvement, reducing missing metadata to less than 2%. This case illustrates how sponsor audits directly impact data quality.

Risk-Based Audit Models for Sponsors

Given the complexity of global trials, risk-based models are increasingly favored. Instead of applying uniform scrutiny across all CRO activities, sponsors now prioritize audits based on risk level. This includes:

• Identifying critical data points such as primary endpoints and SAE reporting.
• Ranking CROs based on geographic risk, prior inspection history, and study complexity.
• Conducting focused audits on high-risk processes, while using remote assessments for lower-risk areas.

For example, a sponsor managing a rare disease trial with decentralized data sources concentrated audits on device data integrity, while applying lighter oversight to standard lab vendor processes.

CAPA Management Following CRO Audits

No audit is complete without a structured CAPA response. A typical CAPA cycle for CRO audit findings includes:

• Audit Finding: Incomplete EDC audit trail reviews.
• Root Cause: Lack of SOP-defined frequency of reviews.
• Corrective Action: Establish weekly audit trail review procedures.
• Preventive Action: Train CRO staff and include monitoring in the QMS dashboard.

Regulators expect sponsors to verify implementation and effectiveness of CRO CAPAs. Simply documenting a response without sponsor follow-up is insufficient.

Best Practices for Sponsor CRO Data Audits

Effective sponsor oversight can be achieved through the following practices:

• Develop detailed audit checklists for CRO-managed systems.
• Maintain joint governance meetings with CRO QA representatives.
• Use audit metrics to trend compliance over time.
• Document all oversight activities within the sponsor’s QMS.
• Include data integrity verification in every audit report.

Conclusion: Strengthening Sponsor-CRO Partnerships

Auditing CRO data management practices is both a regulatory requirement and a strategic necessity. By adopting risk-based models, enforcing CAPA, and maintaining transparent governance, sponsors can ensure compliance and improve data quality. Audits are not just fault-finding missions but opportunities to strengthen sponsor-CRO collaboration and improve trial outcomes.

For reference on trial oversight and CRO audit expectations, consult the ClinicalTrials.gov regulatory resources, which highlight data standards and compliance obligations.

The Sponsor’s Role in Ensuring eTMF Audit Trail Compliance

Why Sponsor Involvement in Audit Trail Reviews Is Critical

In the context of clinical trial documentation, the sponsor is ultimately responsible for ensuring that the electronic Trial Master File (eTMF) is accurate, complete, and inspection-ready. One of the most vital components of TMF oversight is the review of audit trails — system-generated logs that document every action taken on clinical trial records. While Contract Research Organizations (CROs) may handle day-to-day TMF operations, sponsors are accountable under ICH GCP and local regulations for oversight and compliance.

The FDA and EMA expect that sponsors not only validate their systems and delegate appropriately but also maintain visibility into all audit trail records — especially for critical documents like protocols, Investigator Brochures (IBs), and Informed Consent Forms (ICFs). A lack of sponsor oversight can lead to major inspection findings related to data integrity and traceability.

Regulatory Foundations of Sponsor Responsibility

According to ICH E6(R2), the sponsor must ensure that “trial master files are established and maintained and that they are readily available for inspection.” This includes the systems used to manage the TMF — and the audit trails those systems generate. Regulatory references supporting sponsor involvement include:

• ICH GCP E6(R2): Section 5.1.1 – Sponsor retains responsibility for overall trial conduct, even when duties are delegated.
• EMA Reflection Paper on TMF: Emphasizes audit trail review as part of sponsor oversight obligations.
• FDA BIMO Program: Frequently cites sponsor failure to verify TMF audit trails as a GCP deficiency.

This means sponsors must actively engage in audit trail review workflows, approve related SOPs, and request regular reports or dashboards from CRO partners handling TMF documentation.

Types of Audit Trail Reviews Sponsors Should Perform

Sponsors are not expected to review every single audit log entry — but they must implement a risk-based approach to periodic oversight. Key activities include:

• Reviewing audit trails for protocol versions and approvals
• Validating that informed consent documents follow change control procedures
• Confirming finalization and QC of essential documents (e.g., monitoring reports)
• Cross-checking CRO QC workflows against system logs
• Ensuring deletion or document replacement actions are properly justified and logged

Consider this example:

Tracking and confirming these activities supports both data integrity and regulatory compliance.

Formalizing Sponsor Oversight of Audit Trails

Sponsor involvement must be embedded in standard operating procedures (SOPs), quality agreements, and monitoring plans. This ensures clarity across internal and outsourced teams. The sponsor’s audit trail review process should include:

• Frequency of audit trail review (monthly, quarterly, per milestone)
• List of critical documents requiring direct sponsor audit trail checks
• Escalation protocols for discrepancies or unauthorized changes
• Defined user roles with read-only access to audit logs
• Documentation of sponsor review in a TMF audit log or sponsor QC tracker

This process must also align with the CRO’s document management and eTMF access model. All stakeholders should agree on who performs initial reviews, who approves final versions, and who monitors audit logs over time.

Technology Solutions That Facilitate Sponsor Audit Trail Access

Most modern eTMF platforms offer sponsor-side access to real-time audit logs. Sponsors should ensure their systems or CRO platforms allow:

• Dashboards showing audit trail trends (e.g., document deletions, delayed approvals)
• Searchable logs by document ID, action type, or user
• Export functions (CSV, PDF) for inspector presentation
• Email alerts for high-risk changes (e.g., deletion, version replacement)
• Role-based access without edit rights

For example, the sponsor can configure alerts to notify the QA lead if any document in the “Essential Documents” category is revised without an associated approval entry within 48 hours.

Sponsor-CRO Collaboration for Shared Oversight

Clear expectations must be set between sponsors and CROs regarding audit trail handling. The quality agreement should address:

• Which audit trails the CRO reviews vs which the sponsor reviews
• How sponsor feedback is documented and acted upon
• Timelines for escalation and resolution of audit trail concerns
• Joint periodic audit trail assessments (especially pre-inspection)

Regular alignment meetings — monthly or quarterly — should include review of audit trail metrics and a summary of anomalies flagged during the period. Sponsors must be empowered to ask questions and request additional log samples as needed.

Training Sponsor Personnel on Audit Trail Oversight

Sponsors should not assume all internal stakeholders understand audit trail functionality. Training is essential and should include:

• Overview of audit trail regulatory expectations (FDA, EMA, MHRA)
• Live demos of navigating the eTMF system to access logs
• How to read and interpret audit trail entries
• What anomalies to look for (e.g., rapid version changes, missing approvals)
• How to document sponsor reviews and follow-ups

Documented training logs should be retained in the TMF as part of inspection readiness materials.

Case Study: How Sponsor Oversight Prevented an Inspection Finding

In a recent Phase III inspection by the FDA, a CRO had mistakenly uploaded a site closeout report under the incorrect study ID and then replaced it without documented justification. The sponsor’s QA team, performing a routine quarterly audit trail review, caught the replacement and requested a corrective log note. This action was documented and explained proactively during the inspection, avoiding a potential GCP finding.

This example illustrates how sponsor audit trail oversight — even if periodic — provides critical assurance for data integrity.

Checklist: Sponsor Responsibilities for Audit Trail Reviews

• Are sponsor roles for audit trail review defined in SOPs?
• Is there read-only access to CRO audit logs?
• Are high-risk documents reviewed by the sponsor at defined intervals?
• Are issues identified by the sponsor tracked and resolved?
• Are joint audit trail reviews planned pre-inspection?
• Are sponsor reviewers trained in audit trail systems?
• Is sponsor feedback documented in QC trackers or CAPA logs?

Conclusion

Regulatory agencies place final responsibility for trial documentation integrity squarely on the sponsor. In the age of electronic TMFs and increasing reliance on CROs, sponsor oversight of audit trails is more important than ever. Implementing structured review processes, leveraging technology, training internal teams, and fostering sponsor-CRO collaboration can collectively ensure audit trail readiness and protect against regulatory risk.

To explore transparency models and public audit histories, visit WHO’s International Clinical Trials Registry Platform.

Understanding the Key Differences Between Regional and Global CROs

Choosing the right Contract Research Organization (CRO) is a crucial decision that influences clinical trial success. One of the first considerations is whether to partner with a regional CRO or a global one. While both can offer value, understanding their differences in scope, expertise, infrastructure, and regulatory coverage helps sponsors make informed outsourcing decisions. This tutorial breaks down the distinctions between regional and global CROs to support strategic selection aligned with trial needs.

What Is a Regional CRO?

A regional CRO operates primarily within a specific country or set of neighboring countries. These organizations tend to specialize in a particular regulatory environment, therapeutic area, or local trial management. They often have:

• Deep knowledge of local regulations and ethics committees
• Strong site relationships within a defined geography
• Limited but focused infrastructure and headcount
• Cost advantages due to localized operations

What Is a Global CRO?

A global CRO has multinational operations and the capacity to run trials across continents. These CROs typically serve large biopharma clients and are capable of managing Phase I–IV trials in multiple regulatory jurisdictions simultaneously. Their features include:

• End-to-end trial management across regions
• Dedicated teams for regulatory, biometrics, pharmacovigilance, etc.
• Standardized systems for data and computer system validation
• Higher overhead and standardized global pricing

Comparing Key Parameters

1. Geographic Coverage

• Regional CROs: Operate in one country or region; strong knowledge of local healthcare systems and language
• Global CROs: Support multinational trials across North America, Europe, Asia-Pacific, and LATAM

2. Regulatory Experience

• Regional CROs: High expertise in country-specific regulations (e.g., CDSCO for India)
• Global CROs: Experience handling complex filings with EMA, USFDA, and global health authorities

3. Site Access and Relationships

• Regional CROs: Strong relationships with local investigators, hospitals, and ethics boards
• Global CROs: Access to expansive site networks and centralized feasibility tools

4. Cost Structure

• Regional CROs: Lower operational costs, flexible pricing
• Global CROs: Premium pricing, centralized budgeting, but higher predictability

5. Trial Complexity Management

• Regional CROs: Suitable for early phase or localized studies
• Global CROs: Ideal for pivotal, multi-country Phase III studies

Use Cases for Regional vs Global CROs

When to Choose a Regional CRO

• Running single-country or regional studies
• Working with limited budgets
• Needing strong local regulatory navigation
• Prioritizing close site relationships and language familiarity

When to Choose a Global CRO

• Conducting large-scale, multi-country trials
• Requiring standardized systems (e.g., centralized EDC, pharmacovigilance)
• Needing strategic regulatory guidance in multiple regions
• Seeking unified timelines and accountability for global program delivery

Hybrid Models: Best of Both Worlds

Many sponsors adopt a hybrid model where a global CRO oversees trial strategy and systems while regional CROs manage on-the-ground activities. For instance:

• Global CRO leads data management and safety reporting
• Regional CRO handles local site monitoring and ethics submissions

This approach provides the reach of a global partner with the regional nuance necessary for execution quality.

Challenges in Working with Each Model

Regional CRO Challenges

• Limited scalability for global expansion
• Variability in quality systems across regions
• Less experience with global regulatory inspections

Global CRO Challenges

• Higher costs
• Risk of generic processes not adapted to local challenges
• Longer onboarding and contracting processes

How to Decide

Consider the following decision framework:

1. Is the trial local, regional, or global?
2. What is the trial phase and complexity level?
3. Do you need niche therapeutic expertise or broad operational capacity?
4. How critical is regulatory alignment across countries?
5. What budget constraints exist?

Use this to score options in a selection matrix and conduct pre-award audits to confirm capabilities.

Conclusion: Tailor Your CRO Choice to Trial Strategy

Regional and global CROs each offer distinct strengths. While regional CROs bring proximity and cultural fluency, global CROs offer scale, consistency, and multi-region coordination. Sponsors that align their CRO model with trial strategy, budget, and risk appetite will enjoy better operational control, regulatory alignment, and successful trial execution.

Best Practices for Effective CRO Oversight in Clinical Trials

As clinical trial complexity grows and outsourcing becomes more prevalent, sponsors must implement structured oversight of Contract Research Organizations (CROs). Regulatory authorities like the USFDA and EMA emphasize that ultimate responsibility for trial quality and compliance rests with the sponsor, even when activities are outsourced. This article outlines best practices for CRO oversight to ensure trials run efficiently, ethically, and in compliance with Good Clinical Practice (GCP) guidelines.

Why CRO Oversight Is Essential

CRO oversight is not optional. It is a regulatory obligation and a strategic requirement. Without effective oversight, sponsors may face:

• Protocol deviations and data quality issues
• Regulatory inspection findings
• Budget overruns and missed timelines
• Loss of control over critical trial deliverables

Sponsor oversight ensures accountability, transparency, and risk mitigation across the trial lifecycle.

Establish a CRO Oversight Plan

The foundation of effective oversight is a documented CRO Oversight Plan. This plan should:

• Define roles and responsibilities
• Detail communication pathways and escalation processes
• Include risk-based monitoring strategies
• Specify key performance indicators (KPIs) and metrics
• Align with GCP, GMP compliance, and ICH E6(R2) guidelines

Assign Clear Roles and Responsibilities

Use a RACI (Responsible, Accountable, Consulted, Informed) matrix to allocate oversight duties across sponsor departments:

• Clinical Operations – protocol compliance and issue resolution
• Quality Assurance – audit planning and CAPA follow-up
• Regulatory Affairs – submission timelines and deviation reporting
• Data Management – EDC system performance and query resolution
• Procurement – contract terms and budget tracking

Set Clear Oversight Metrics

Monitor CRO performance using measurable KPIs:

• Enrollment rates vs. target
• Query resolution timelines
• Number of protocol deviations
• Monitor visit frequency and reports submitted
• Data lock timelines and interim deliverables

Review metrics monthly or quarterly, and document any trends or outliers for follow-up.

Conduct Regular Oversight Meetings

Schedule routine meetings based on trial stage:

• Start-up Phase: Weekly meetings to align expectations and SOPs
• Active Phase: Biweekly or monthly reviews of site performance and deliverables
• Close-out Phase: Final reconciliation and audit preparation

Maintain agendas and minutes as part of the Stability Studies or clinical trial documentation system.

Audit the CRO Periodically

Sponsor QA teams should audit the CRO at regular intervals to assess:

• Adherence to SOPs and regulatory expectations
• Timeliness and completeness of monitoring activities
• Training records and documentation practices
• Root cause analysis of recurring issues

Refer to Pharma SOP templates for audit report formats and follow-up CAPA tracking.

Implement Risk-Based Oversight

Focus oversight efforts on high-risk areas, such as:

• First-in-human or rare disease trials
• Geographically dispersed trial sites
• Newly qualified CROs
• Critical milestones like interim analyses or database locks

Use risk assessment tools and heat maps to prioritize focus areas.

Escalation and Issue Management

Establish a documented escalation path for handling deviations, safety concerns, or performance lapses. This includes:

• First-line review by clinical operations
• Escalation to vendor governance team
• CAPA planning and implementation
• Root cause analysis and systemic fixes

Maintain an Oversight File

Maintain an oversight file including:

• Oversight plan
• Meeting minutes
• KPI dashboards
• Audit reports and CAPAs
• Communications and escalation logs

This file is critical for sponsor inspections by regulators like CDSCO or Health Canada.

Leverage Technology in Oversight

Use dashboards, electronic Trial Master Files (eTMFs), and communication platforms for real-time oversight. Integrated systems allow automated KPI tracking and proactive risk identification. Review the validation master plan for computerized systems used in vendor oversight.

Conclusion: Oversight Is a Continuous Process

CRO oversight is not a one-time activity but an ongoing process throughout the trial lifecycle. Sponsors that implement structured oversight plans, monitor KPIs, conduct regular audits, and foster transparent communication with CROs will see better trial outcomes, stronger regulatory compliance, and reduced operational risks.

How to Involve CROs in Site Feasibility Planning for Clinical Trials

Contract Research Organizations (CROs) play a pivotal role in modern clinical trials, particularly in site feasibility and selection. Involving CROs early in feasibility planning not only expands site outreach but also introduces process efficiencies, global expertise, and technology infrastructure. This guide outlines best practices for incorporating CROs into site feasibility planning to ensure high-performing site selection, compliance, and faster trial start-up.

Why Involve CROs in Site Feasibility?

CROs offer significant advantages in feasibility planning due to their:

• Established relationships with investigational sites worldwide
• Dedicated feasibility teams with therapeutic area expertise
• Experience in managing multi-country regulations and submissions
• Access to data-driven site performance metrics
• Digital infrastructure like CTMS and feasibility platforms

When to Engage CROs in the Feasibility Process

Engagement should begin at the protocol synopsis stage and continue through site selection:

1. Protocol Development: CROs provide input on operational feasibility (e.g., visit frequency, lab needs)
2. Site Outreach: Use CRO databases and local teams for PI engagement
3. Questionnaire Distribution and Follow-up: CROs manage the flow of feasibility forms, reminders, and clarifications
4. Site Scoring and Final Selection: Joint CRO-sponsor committees evaluate sites using objective metrics

CRO Responsibilities in Feasibility Planning

1. Site Identification and Pre-Screening

• Utilize internal databases and historic trial records to shortlist high-performing sites
• Assess site capacity, recruitment history, and infrastructure readiness
• Ensure geographic distribution matches protocol needs

2. Questionnaire Management and Analysis

• Customize feasibility forms using sponsor-provided or CRO templates
• Deploy through platforms like REDCap or CTMS-integrated tools
• Analyze responses for red flags (e.g., conflicting trials, resource constraints)

3. PI Interviews and Site Qualification

• Conduct virtual or on-site PI interviews using structured checklists
• Evaluate staff availability, SOP alignment, and trial engagement
• Document findings and store them within the Trial Master File (TMF)

4. Regulatory and Operational Readiness Assessment

• Verify ethics committee access and approval timelines
• Assess documentation capabilities (CVs, GCP, lab certifications)
• Coordinate logistics planning for IP storage, sample shipment, and equipment readiness

Sponsor Oversight and Collaboration

Despite outsourcing, sponsors retain ultimate responsibility for site selection. Effective collaboration includes:

• Feasibility kickoff meetings with the sponsor, CRO, and clinical operations
• Joint review of final feasibility criteria and scoring models
• Regular updates via dashboards and shared documents
• Final site selection meeting with clear documentation of decisions

Feasibility Tools and Templates Used by CROs

• Feasibility Tracker: Real-time site response and review status
• PI Interview Scripts: Standardized questions for therapeutic areas
• Site Scoring Matrices: Weighted criteria for quantitative selection
• Site Selection Summary: Justification memo for audit trail
• Templates from Pharma SOP documentation to ensure SOP-compliant records

Challenges in CRO-Sponsor Feasibility Planning

• Over-standardization: Templates may miss protocol-specific nuances
• Delayed communication: Decision-making bottlenecks without joint alignment
• Inconsistent metrics: Varying interpretations of site scoring across teams
• Insufficient documentation: Non-auditable records in case of regulatory review

Mitigation Strategies

1. Use shared feasibility SOPs between sponsor and CRO
2. Ensure CRO team receives protocol training and therapeutic context
3. Standardize scoring and decision rules across both organizations
4. Audit the feasibility process at CROs to confirm compliance with USFDA and ICH GCP

Regulatory Documentation

Feasibility decisions and CRO engagement must be documented and archived in the TMF. According to CDSCO and EMA guidelines, sponsors must justify site selection and demonstrate due diligence—even when working with a CRO.

Conclusion

Involving CROs in site feasibility planning empowers sponsors to scale operations, access experienced networks, and optimize start-up timelines. However, this collaboration must be governed by clear roles, structured SOPs, and consistent communication. When executed correctly, CRO-supported feasibility delivers compliant, data-driven site selection that sets trials up for success.